Published in Medical Letter on the CDC and FDA, December 17th, 2006
These applications could potentially be used to treat a wide variety of common dermatologic conditions that are extremely problematic to treat.
"Having successfully completed a preliminary wound healing study at the University of Miami, as well as completing a phase I study confirming safety, we are ready to begin a phase II pilot study in patients with common skin problems. Based on recent discussions with clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.